Department of Cardiology, Concord Hospital, The University of Sydney, Sydney, NSW, Australia.
Department of Cardiology, Concord Hospital, The University of Sydney, Sydney, NSW, Australia.
Heart Lung Circ. 2021 Aug;30(8):1213-1220. doi: 10.1016/j.hlc.2021.02.007. Epub 2021 Mar 12.
The increasing implementation of transcatheter aortic valve implantation (TAVI) in Australia warrants real-world data on the prevalence and outcomes of these patients. The aim of this study is to describe trends in case-volumes of TAVI in New South Wales (NSW), Australia and associated mortality outcomes.
From the Centre of Health Record Linkage registry, all NSW residents who underwent TAVI between 5 June 2013 and 30 June 2018 were identified. Cause-specific mortality was tracked from the statewide death registry. Temporal trends in case-volumes between 2013 and 2018 were assessed by linear regression. Binary logistic regression was used to compare differences in in-hospital and 30-day mortality, while Cox proportional hazards regression was used to compare mortality beyond 30 days.
Case-volumes increased from 30 in 2013 to 345 by 2017. The cohort comprised 1,098 persons (mean[±SD] age: 83.3±7.7 yrs). Cumulative in-hospital, 180-day and at end-of-study (mean: 1.8±1.2 yrs) all-cause mortality were 1.3% (n=14), 4.9% (n=54) and 20.3% (n=224) respectively. Heart failure (14.3%, n=2), myocardial infarction (14.3%, n=2), and sepsis (14.3%, n=2) were the primary causes of in-hospital death. Post-discharge, sepsis (25.2%, n=53) was the main cause-specific death, while combined cardiovascular deaths accounted for 46% (n=97), mostly from heart failure (n=35). Heart failure, chronic kidney disease, and requirement for ventilation post-TAVI were independent predictors of in-hospital death and at 180 days. TAVI procedure in low-volume public centres was a predictor of mortality at 180 days.
The number of TAVI procedures increased 10-fold between 2013 and 2017 state-wide, with mortality rates comparable to international cohorts at short and medium-term follow-up. Pre-existing comorbidities and site-specific caseloads may be important determinants of outcome, emphasising the importance of appropriate patient selection and treating centre.
经导管主动脉瓣植入术(TAVI)在澳大利亚的应用日益广泛,因此需要了解该手术在真实世界中的患者数量和预后情况。本研究旨在描述新南威尔士州(NSW)TAVI 病例数量的变化趋势及其相关的死亡率。
从健康记录链接中心的登记处中,确定了 2013 年 6 月 5 日至 2018 年 6 月 30 日期间在新南威尔士州接受 TAVI 的所有居民。通过全州死亡登记处对特定原因的死亡率进行跟踪。通过线性回归评估 2013 年至 2018 年期间病例数量的时间趋势。使用二元逻辑回归比较住院和 30 天死亡率的差异,使用 Cox 比例风险回归比较 30 天以上的死亡率。
病例数量从 2013 年的 30 例增加到 2017 年的 345 例。该队列包括 1098 人(平均[±标准差]年龄:83.3±7.7 岁)。住院期间、180 天和研究结束时(平均:1.8±1.2 年)的全因死亡率分别为 1.3%(n=14)、4.9%(n=54)和 20.3%(n=224)。心力衰竭(14.3%,n=2)、心肌梗死(14.3%,n=2)和败血症(14.3%,n=2)是住院期间死亡的主要原因。出院后,败血症(25.2%,n=53)是主要的特定原因死亡,而心血管联合死亡占 46%(n=97),主要来自心力衰竭(n=35)。心力衰竭、慢性肾脏病和 TAVI 后需要通气是住院期间死亡和 180 天的独立预测因素。低容量公共中心的 TAVI 手术是 180 天死亡率的预测因素。
2013 年至 2017 年期间,TAVI 手术的数量增加了 10 倍,短期和中期随访的死亡率与国际队列相当。预先存在的合并症和特定部位的病例量可能是结果的重要决定因素,强调了适当的患者选择和治疗中心的重要性。